Free Trial

Denali Therapeutics (DNLI) Stock Price, News & Analysis

-0.38 (-1.85%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
856,052 shs
Average Volume
1.16 million shs
Market Capitalization
$2.87 billion
P/E Ratio
Dividend Yield
Price Target

Denali Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
99.8% Upside
$40.22 Price Target
Short Interest
8.16% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.61mentions of Denali Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.93 M Sold Last Quarter
Proj. Earnings Growth
From ($2.77) to ($2.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.29 out of 5 stars

Medical Sector

150th out of 918 stocks

Biological Products, Except Diagnostic Industry

15th out of 147 stocks

DNLI stock logo

About Denali Therapeutics Stock (NASDAQ:DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Stock Price History

DNLI Stock News Headlines

DNLI Apr 2024 12.500 put
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$330.53 million
Book Value
$7.42 per share


Free Float
Market Cap
$2.87 billion

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ryan J. Watts Ph.D. (Age 48)
    Co-Founder, President, CEO & Director
    Comp: $1.15M
  • Dr. Alexander O. Schuth M.D.Dr. Alexander O. Schuth M.D. (Age 51)
    Co-Founder, CFO, COO & Secretary
    Comp: $802.29k
  • Dr. Marc Tessier-Lavigne Ph.D. (Age 64)
    Co-Founder & Independent Director
    Comp: $57.5k
  • Dr. Carole Ho M.D. (Age 51)
    Chief Medical Officer & Head of Development
    Comp: $802.29k
  • Mr. Tyler M. Nielsen (Age 46)
    Senior Vice President of Corporate Finance
  • Dr. Dana Andersen
    Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock Ph.D.
    Chief Scientific Officer
  • Dr. Laura Hansen
    Vice President of Investor Relations
  • Mr. Chris Walsh
    General Counsel
  • Mr. Mark Rowen
    Vice President of Corporate Development

DNLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price target for 2024?

9 equities research analysts have issued 12 month target prices for Denali Therapeutics' stock. Their DNLI share price targets range from $22.00 to $95.00. On average, they predict the company's stock price to reach $40.22 in the next year. This suggests a possible upside of 99.8% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2024?

Denali Therapeutics' stock was trading at $21.46 at the beginning of 2024. Since then, DNLI stock has decreased by 6.2% and is now trading at $20.13.
View the best growth stocks for 2024 here

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our DNLI earnings forecast

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 11.46%. During the same period in the previous year, the company earned ($0.80) EPS.

What ETFs hold Denali Therapeutics' stock?

ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV).

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (9.85%), Vanguard Group Inc. (7.69%), Capital Research Global Investors (4.24%), Baker BROS. Advisors LP (2.62%), Price T Rowe Associates Inc. MD (1.12%) and Principal Financial Group Inc. (0.79%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DNLI) was last updated on 5/21/2024 by Staff

From Our Partners